Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867823 | 0.89 | GPR119 (0.37) | LMNATHRBTP53 | |
| SCHEMBL30911193 | 0.89 | GPR119 (0.37) | LMNATHRBTP53 | |
| SCHEMBL30867732 | 0.83 | TP53 (0.48) | LMNATHRBMEN1ALDH1A1GAA | |
| SCHEMBL38654024 | 0.75 | CHRM2 (0.34) | LMNATHRBMAPTTP53 | |
| SCHEMBL38653670 | 0.72 | MEN1 (0.48) | LMNATHRBMEN1ALDH1A1GAA | |
| SCHEMBL31320104 | 0.71 | EPHX2 (0.39) | THRBMAPTMEN1ALDH1A1GAA | |
| SCHEMBL31320106 | 0.71 | EPHX2 (0.39) | THRBMAPTMEN1ALDH1A1GAA | |
| SCHEMBL31380056 | 0.71 | EPHX2 (0.39) | THRBMAPTMEN1ALDH1A1GAA | |
| SCHEMBL30867752 | 0.70 | PIK3CD (0.33) | TP53 | |
| SCHEMBL27320984 | 0.69 | NPSR1 (0.38) | LMNATHRBMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 1584/4885THRB 3357/4885MAPT 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.